Sodium-glucose cotransporter 2 inhibitors (SGLT2is) lowered the risk of chronic kidney disease (CKD) progression regardless of patients’ estimated glomerular filtration rate (eGFR) or albuminuria, according to authors of a study published in…
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) lowered the risk of chronic kidney disease (CKD) progression regardless of patients’ estimated glomerular filtration rate (eGFR) or albuminuria, according to authors of a study published in…